Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05912335 |
Other study ID # |
CAAE: 45317521.9.0000.5418 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 1
|
First received |
|
Last updated |
|
Start date |
June 2, 2021 |
Est. completion date |
May 3, 2022 |
Study information
Verified date |
June 2023 |
Source |
University of Campinas, Brazil |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
In a crossover, randomized, placebo-controlled, double-blind study, 40 volunteers will
receive the following formulations: hydrogels containing LAs (local anesthetic) - lidocaine
and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA (topical
anesthetic available on the market) and placebo hydrogel. The formulations will be applied
for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct
sessions. Soon after removal of the topical formulation, an AL will be performed at the
region using 0.3 mL of anesthetic solution at an injection speed of 1 mL/min. Pain resulting
from needle insertion and LA injection will be measured using two visual analog scales (VAS).
Description:
Dental treatment presents numerous innovations, but the pain associated with the
administration of local anesthesia (LA) continuous to be a traumatic procedure for many
patients. Although we use topical anesthetics (TA) to reduce pain, the commercially available
formulations are only effective in preventing the pain of the needle puncture.
This project aims to evaluate the clinical efficacy of xanthan-based hydrogels (2%)
containing LAs encapsulated in nanostructured lipid carriers (CLN), reducing pain during
puncture and injection of LA in the palatine mucosa. In a crossover, randomized,
placebo-controlled, double-blind study, 40 volunteers will receive the following
formulations: hydrogels containing LAs - lidocaine and prilocaine (both at 2.5%) encapsulated
in CLN (XAN-CLN) or not (XAN-CLN ), EMLA and placebo hydrogel. The formulations will be
applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two
distinct sessions. Soon after the removal of the topical formulation, an AL will be performed
at the region using 0.3 mL of anesthetic solution at an injection speed of 1 mL/min. The
computerized Morpheus® anesthetic injector will be used in order to control the variables of
volume and injection speed. Pain resulting from needle insertion and LA injection will be
measured using two visual analog scales (VAS). Hydrogels containing CLN are expected to have
good mechanical properties and allow the permeation of LAs efficiently through the oral
mucosal epithelium. In addition, they can improve the efficacy of topical anesthesia in order
to perform a painless LA in the palatal mucosa.